Cohlhepp Ryan: insider trades.
Cohlhepp Ryan reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($1.8M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 7
- Companies
- 1
- Name as filed
- Cohlhepp Ryan
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Bicara Therapeutics Inc. (BCAX) | Director, Officer · President, COO & Interim CEO | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Bicara Therapeutics Inc. | S | 3,442 | $23.43 | 181,641 | Form 4 |
| 2026-09-08 | Bicara Therapeutics Inc. | S | 14,058 | $22.77 | 185,083 | Form 4 |
| 2026-09-08 | Bicara Therapeutics Inc. | M | 17,500 | $3.79 | 199,141 | Form 4 |
| 2026-08-10 | Bicara Therapeutics Inc. | M | 18,750 | $3.79 | 200,391 | Form 4 |
| 2026-08-10 | Bicara Therapeutics Inc. | S | 18,750 | $27.98 | 181,641 | Form 4 |
| 2026-07-09 | Bicara Therapeutics Inc. | S | 536 | $29 | 181,641 | Form 4 |
| 2026-07-08 | Bicara Therapeutics Inc. | M | 18,750 | $3.79 | 210,391 | Form 4 |
| 2026-07-08 | Bicara Therapeutics Inc. | S | 22,833 | $28.76 | 187,558 | Form 4 |
| 2026-07-08 | Bicara Therapeutics Inc. | S | 1,075 | $30.35 | 182,177 | Form 4 |
| 2026-07-08 | Bicara Therapeutics Inc. | S | 4,306 | $29.8 | 183,252 | Form 4 |
Questions
What stock did Cohlhepp Ryan buy or sell?
Cohlhepp Ryan reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($1.8M), across 1 company.
Is Cohlhepp Ryan the same person as other filers with this name?
This page covers SEC CIK 2034665 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/cohlhepp-ryan-2034665.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.